Key facts
- It has raised $25.0M; the latest was PE Growth/Expansion ($25.0M) in Nov 2025.
- Notable investors include PAG, Signet Healthcare Partners.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for RK Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for RK Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RK Pharma
Manufacturer of generic pharmaceutical products designed to focus on products with formulation challenges and first generic opportunities. The company specializes in managing a seamless process of bulk manufacturing through multi-format packaging and end-product release testing suited for injectables, sterile ophthalmic and dermal products, enabling clients to get a broad range of affordable and effective therapeutic products for patients.
- Sector
- Healthcare
- HQ
- Pearl River, NY, United States
- Founded
- 2003
- Employees
- 1,700
- Website
- rkpharmainc.com/
- Ownership
- Privately Held (backing)
RK Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RK Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RK Pharma in its N-PORT filings yet. We sweep new filings monthly.